Announcements Trials
Browse Landscape

Status

Completed 9Unknown 6Recruiting 5Withdrawn 1Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Head & Neck 1CNS 1Breast 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1

Interventions

olverembatinib 1ibrutinib 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1Melphalan 1JNJ-64619178 1JNJ-64264681 1Imatinib Mesylate 1Busulfan 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Blood Specimen Collection × Myeloid × Clear all
NCT01728402 2026-02-17

Pathogenesis of Hematologic Malignancies

OHSU Knight Cancer Institute

Enrolling by invitation
5,000 enrolled
LymphoidMyeloid

Lymphoproliferative Disorders, Myelodysplastic Syndromes, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡